Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HLM1196
- Development stage
- Preclinical
- Lead developer
- Helmholtz Zentrum München
- Modality
- Small Molecules
01
Overview
HLM1196 is a novel, highly potent small molecule anti-fibrotic compound belonging to the N-(2-butoxyphenyl)-3-(phenyl)acrylamide (N23P) class. Developed by researchers at Helmholtz Zentrum München (Helmholtz Munich) and partners, HLM1196 was optimized via medicinal chemistry from the parent scaffold of tranilast to enhance potency while eliminating NOX4 and pro-Wnt liabilities. Mechanistically, HLM1196 acts as a selective microtubule destabilizer. It induces cell rounding and collapses cellular tensegrity in primary human lung fibroblasts, leading to a mitotic catastrophe signature in CTHRC1+ myofibroblasts and reversing integrin-linked signaling in KRT17+ aberrant basaloid cells. HLM1196 is being investigated for the treatment of idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis.
- Other names
- N23PN-23PN 23PN23PsN-23PsN 23Ps
02
Targets
TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on HLM1196.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HLM1196.